- Home
- Publications
- Publication Search
- Publication Details
Title
Novel and Emerging Therapies for Inflammatory Bowel Disease
Authors
Keywords
-
Journal
Frontiers in Pharmacology
Volume 12, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2021-04-14
DOI
10.3389/fphar.2021.651415
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Apremilast, an Oral Inhibitor of Phosphodiesterase 4, in a Randomized Trial of Patients With Active Ulcerative Colitis
- (2020) Silvio Danese et al. Clinical Gastroenterology and Hepatology
- Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis
- (2020) William J. Sandborn et al. GASTROENTEROLOGY
- Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease
- (2020) William J. Sandborn et al. GASTROENTEROLOGY
- P420 A randomised, observer-blinded phase Ib multiple, ascending dose study of UTTR1147A, an IL-22Fc fusion protein, in healthy volunteers and ulcerative colitis patients
- (2020) F Wagner et al. Journal of Crohns & Colitis
- OP27 Long-term safety and efficacy of risankizumab treatment in patients with Crohn’s disease: Final results from the Phase 2 open-label extension study
- (2020) M Ferrante et al. Journal of Crohns & Colitis
- Etrolizumab for the Treatment of Ulcerative Colitis and Crohn’s Disease: An Overview of the Phase 3 Clinical Program
- (2020) William J. Sandborn et al. ADVANCES IN THERAPY
- Development of Gut-Selective Pan-Janus Kinase Inhibitor TD-1473 for Ulcerative Colitis: A Translational Medicine Programme
- (2020) William J Sandborn et al. Journal of Crohns & Colitis
- TYK2/JAK1 Inhibitor PF-06700841 in Patients with Plaque Psoriasis: Phase IIa, Randomized, Double-blind, Placebo-controlled Trial
- (2020) Seth B. Forman et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- JAK–STAT pathway targeting for the treatment of inflammatory bowel disease
- (2020) Azucena Salas et al. Nature Reviews Gastroenterology & Hepatology
- Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis
- (2020) Einat Almon et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study
- (2020) Brian G Feagan et al. Lancet Gastroenterology & Hepatology
- Efficacy and Safety of Continued Treatment with Mirikizumab in a Phase 2 Trial of Patients with Ulcerative Colitis
- (2020) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial
- (2020) Raja Atreya et al. Lancet Gastroenterology & Hepatology
- DOP48 Amiselimod, a selective S1P receptor modulator in Crohn’s disease patients: a proof-of-concept study
- (2019) G D’Haens et al. Journal of Crohns & Colitis
- Systematic review and meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease
- (2019) Christopher Ma et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- 1003 – Efficacy and Safety of Mirikizumab (LY3074828) in a Phase 2 Study of Patients with Crohn's Disease
- (2019) Bruce E. Sands et al. GASTROENTEROLOGY
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Efficacy and Safety of Mirikizumab in a Randomized Phase 2 Study of Patients With Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- Anti-interleukin-23 agents for the treatment of ulcerative colitis
- (2019) Jurij Hanžel et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Efficacy and Safety of Etrasimod in a Phase 2 Randomized Trial of Patients with Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial
- (2019) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial
- (2019) Giancarlo Comi et al. LANCET NEUROLOGY
- Randomized phase 1 healthy volunteer study of UTTR1147A (IL-22Fc), a potential therapy for epithelial injury
- (2018) Michael E Rothenberg et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Herpes Zoster Infection in Patients With Ulcerative Colitis Receiving Tofacitinib
- (2018) Kevin L Winthrop et al. INFLAMMATORY BOWEL DISEASES
- OP024 Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s disease: the OPERA II study
- (2018) G R D’Haens et al. Journal of Crohns & Colitis
- DOP062 The anti-MAdCAM antibody SHP647 in Crohn’s disease: Endoscopic effects of induction therapy
- (2018) G R D′Haens et al. Journal of Crohns & Colitis
- Anti-integrin therapy for inflammatory bowel disease
- (2018) Sung Chul Park et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative Colitis
- (2018) Stephen Hanauer et al. Clinical Gastroenterology and Hepatology
- Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate to Severe Ulcerative Colitis
- (2018) William J. Sandborn et al. GASTROENTEROLOGY
- Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study
- (2017) Bruce E. Sands et al. GASTROENTEROLOGY
- Use of Anti–Tumor Necrosis Factors and Anti-Integrins in the Treatment of Crohn's Disease
- (2017) Raina Shivashankar et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Ustekinumab and Anti-Interleukin-23 Agents in Crohn's Disease
- (2017) Parakkal Deepak et al. GASTROENTEROLOGY CLINICS OF NORTH AMERICA
- Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)
- (2017) Silvio Danese et al. GUT
- Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
- (2017) Julian Panés et al. GUT
- The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a TYK2/JAK1 Inhibitor (PF-06700841) in Healthy Subjects and Patients With Plaque Psoriasis
- (2017) Christopher Banfield et al. JOURNAL OF CLINICAL PHARMACOLOGY
- OP035 Efficacy and safety of abrilumab (AMG 181/MEDI 7183) therapy for moderate to severe Crohn's disease
- (2017) W.J. Sandborn et al. Journal of Crohns & Colitis
- Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration
- (2017) Silvio Danese et al. Journal of Crohns & Colitis
- OP011 Etrolizumab treatment leads to early improvement in symptoms and inflammatory biomarkers in anti-TNF-refractory patients in the open-label induction cohort of the phase 3 HICKORY study
- (2017) L. Peyrin-Biroulet et al. Journal of Crohns & Colitis
- Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
- (2017) Séverine Vermeire et al. LANCET
- Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
- (2017) Brian G Feagan et al. LANCET
- Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis
- (2017) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- AVX-470, an Orally Delivered Anti-Tumour Necrosis Factor Antibody for Treatment of Active Ulcerative Colitis: Results of a First-in-Human Trial
- (2016) M. Scott Harris et al. Journal of Crohns & Colitis
- Clinical Effects of a Topically Applied Toll-like Receptor 9 Agonist in Active Moderate-to-Severe Ulcerative Colitis
- (2016) Raja Atreya et al. Journal of Crohns & Colitis
- Safety and efficacy of amiselimod in relapsing multiple sclerosis (MOMENTUM): a randomised, double-blind, placebo-controlled phase 2 trial
- (2016) Ludwig Kappos et al. LANCET NEUROLOGY
- Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial
- (2016) Jeffrey A Cohen et al. LANCET NEUROLOGY
- Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis
- (2016) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
- (2016) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis
- (2015) Naoki Yoshimura et al. GASTROENTEROLOGY
- Efficacy and Safety of Antiintegrin Antibody for Inflammatory Bowel Disease
- (2015) Lianjie Lin et al. MEDICINE
- Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial
- (2014) Séverine Vermeire et al. LANCET
- Oral treatment with a novel small molecule alpha 4 integrin antagonist, AJM300, prevents the development of experimental colitis in mice
- (2013) Toshihiko Sugiura et al. Journal of Crohns & Colitis
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
- (2011) Natalie A. Molodecky et al. GASTROENTEROLOGY
- Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47
- (2011) Carl A Anderson et al. NATURE GENETICS
- A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
- (2010) Ludwig Kappos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
- (2010) Jeffrey A. Cohen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced PDE4B expression augments LPS-inducible TNF expression in ethanol-primed monocytes: relevance to alcoholic liver disease
- (2008) Leila Gobejishvili et al. AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY
- Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
- (2008) Jeffrey C Barrett et al. NATURE GENETICS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started